Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy

References

• LitvanIBhatiaKPBurnDJMovement Disorders Society Scientific Issues CommitteeMovement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disordersMov Disord200318546748612722160
   PubMed Web of Science ®Google Scholar
• WilliamsDRde SilvaRPaviourDCCharacteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonismBrain2005128Pt 61247125815788542
   PubMed Web of Science ®Google Scholar
• GilmanSWenningGKLowPASecond consensus statement on the diagnosis of multiple system atrophyNeurology200871967067618725592
   PubMed Web of Science ®Google Scholar
• WenningGKGeserFKrismerFEuropean Multiple System Atrophy Study GroupThe natural history of multiple system atrophy: a prospective European cohort studyLancet Neurol201312326427423391524
   PubMed Web of Science ®Google Scholar
• StamelouMQuinnNPBhatiaK“Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supra-nuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guideMov Disord20132891184119923720239
   PubMed Web of Science ®Google Scholar
• AntoniniACiliaRBehavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and preventionDrug Saf200932647548819459715
   PubMed Web of Science ®Google Scholar
• VilasDPont-SunyerCTolosaEImpulse control disorders in Parkinson’s diseaseParkinsonism Relat Disord201218Suppl 1S80S8422166463
   PubMedGoogle Scholar
• SchnitzlerALeffersKWHäckHJHigh compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s diseaseParkinsonism Relat Disord2010161851351620605106
   PubMed Web of Science ®Google Scholar
• TrenkwalderCKiesBRudzinskaMRecover Study GroupRotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER)Mov Disord2011261909921322021
   PubMed Web of Science ®Google Scholar
• BaldwinCMKeatingGMRotigotine transdermal patch: a review of its use in the management of Parkinson’s diseaseCNS Drugs200721121039105518020483
   PubMed Web of Science ®Google Scholar
• PoeweWHRascolOQuinnNSP 515 InvestigatorsEfficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trialLancet Neurol20076651352017509486
   PubMed Web of Science ®Google Scholar
• SanfordMScottLJRotigotine transdermal patch: a review of its use in the treatment of Parkinson’s diseaseCNS Drugs201125869971921790211
   PubMed Web of Science ®Google Scholar
• LeWittPABoroojerdiBSurmannEPoeweWSP716 Study Group; SP715 Study GroupRotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFERJ Neural Transm201312071069108123208198
   PubMed Web of Science ®Google Scholar
• Ray ChaudhuriKMartinez-MartinPAntoniniARotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVERParkinsonism Relat Disord201319766066523557594
   PubMed Web of Science ®Google Scholar
• ZhouCQLiSSChenZMLiFQLeiPPengGGRotigotine transdermal patch in Parkinson’s disease: a systematic review and meta-analysisPLoS One201387e6973823936090
   PubMed Web of Science ®Google Scholar
• WenningGKBen-ShlomoYMagalhãesMDanielSEQuinnNPClinicopathological study of 35 cases of multiple system atrophyJ Neurol Neurosurg Psychiatry19955821601667876845
   PubMed Web of Science ®Google Scholar
• WenningGKTisonFBen ShlomoYDanielSEQuinnNPMultiple system atrophy: a review of 203 pathologically proven casesMov Disord19971221331479087971
   PubMed Web of Science ®Google Scholar
• WenningGKScherflerCGranataRTime course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological studyJ Neurol Neurosurg Psychiatry199967562062310519868
   PubMed Web of Science ®Google Scholar
• WenningGKStefanovaNJellingerKAPoeweWSchlossmacherMGMultiple system atrophy: a primary oligodendrogliopathyAnn Neurol200864323924618825660
   PubMed Web of Science ®Google Scholar
• LitvanIMangoneCAMcKeeANatural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological studyJ Neurol Neurosurg Psychiatry19966066156208648326
   PubMed Web of Science ®Google Scholar
• LitvanIAgidYCalneDClinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshopNeurology1996471198710059
   PubMed Web of Science ®Google Scholar
• WilliamsDRLeesAJProgressive supranuclear palsy: clinicopathological concepts and diagnostic challengesLancet Neurol20098327027919233037
   PubMed Web of Science ®Google Scholar
• LingHO’SullivanSSHoltonJLDoes corticobasal degeneration exist? A clinicopathological re-evaluationBrain2010133Pt 72045205720584946
   PubMed Web of Science ®Google Scholar
• LiscicRMSrulijesKGrögerAMaetzlerWBergDDifferentiation of progressive supranuclear palsy: clinical, imaging and laboratory toolsActa Neurol Scand2013127536237023406296
   PubMed Web of Science ®Google Scholar
• LarsenJPDupontETandbergEThe clinical diagnosis of Parkinson’s disease. Proposal of diagnostic subgroups classified at different levels of confidenceActa Neurol Scand19948942422518042440
   PubMed Web of Science ®Google Scholar
• AarslandDLitvanISalmonDGalaskoDWentzel-LarsenTLarsenJPPerformance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry20037491215122012933921
   PubMed Web of Science ®Google Scholar
• BerardelliAWenningGKAntoniniAEFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s diseaseEur J Neurol20132011634 Erratum in: Eur J Neurol. 2013; 20(2):40623279440
   PubMed Web of Science ®Google Scholar
• StamelouMHoeglingerGUAtypical parkinsonism: an updateCurr Opin Neurol201326440140523812308
   PubMed Web of Science ®Google Scholar
• McKeithIGGalaskoDKosakaKConsensus guidelines for the clinical diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopNeurology1996475111311248909416
   PubMed Web of Science ®Google Scholar
• McKeithIGDicksonDWLoweJet al; Consortium onDLBDiagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumNeurology200565121863187216237129
   PubMed Web of Science ®Google Scholar
• FahnSEltonRLUPDRS Program MembersUnified Parkinson’s disease rating scaleFahnSMarsdenCDGoldsteinMCalneDBRecent Developments in Parkinson’s Disease2Florham Park, NJMacmillan Healthcare Information1987153163293304
   Google Scholar
• CummingsJLMegaMGrayKRosenberg-ThomsonSCarusiDAGornbeinJThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementiaNeurology19944412230823147991117
   PubMed Web of Science ®Google Scholar
• FolsteinMFFolsteinSEMcHughPR“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res1975123189981202204
   PubMed Web of Science ®Google Scholar
• PoeweWBaronePGliadiNA randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtypeMov Disord201227Suppl 1 abstr 1182
   Google Scholar
• NovakPWilliamsARavinPZurkiyaOAbduljalilANovakVTreatment of multiple system atrophy using intravenous immunoglobulinBMC Neurol20121213123116538
   PubMed Web of Science ®Google Scholar
• LeePHLeeJEKimHSA randomized trial of mesenchymal stem cells in multiple system atrophyAnn Neurol2012721324022829267
   PubMed Web of Science ®Google Scholar
• HöglingerGUHuppertzHJWagenpfeilSTAUROS MRI InvestigatorsTideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trialMov Disord201429447948724488721
   PubMed Web of Science ®Google Scholar
• StamelouMde SilvaRArias-CarriónORational therapeutic approaches to progressive supranuclear palsyBrain2010133Pt 61578159020472654
   PubMed Web of Science ®Google Scholar
• LiebermanAOlanowCWSethiKA multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study GroupNeurology1998514105710629781529
   PubMed Web of Science ®Google Scholar
• LiebermanARanhoskyAKortsDClinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group studyNeurology19974911621689222185
   PubMed Web of Science ®Google Scholar
• LeWittPALyonsKEPahwaRSP 650 Study GroupAdvanced Parkinson disease treated with rotigotine transdermal system: PREFER studyNeurology200768161262126717438216
   PubMed Web of Science ®Google Scholar
• GeorgievDDanieliAOcepekLOthello syndrome in patients with Parkinson’s diseasePsychiatr Danub2010221949820305599
   PubMed Web of Science ®Google Scholar
• SchellerDUllmerCBerkelsRGwarekMLübbertHThe in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s diseaseNaunyn Schmiedebergs Arch Pharmacol20093791738618704368
   PubMed Web of Science ®Google Scholar
• SchellerDStichel-GunkelCLübbertHNeuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s diseaseNeurosci Lett2008432130418162314
   PubMed Web of Science ®Google Scholar
• ZanettiniRAntoniniAGattoGGentileRTeseiSPezzoliGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med20073561394617202454
   PubMed Web of Science ®Google Scholar